Results 31 to 40 of about 20,432 (139)
Efavirenz is inhibitor of non-nucleoside reverse transcriptase enzyme; BCS class II drug. The objective of the present research was to prepare and evaluate nanosuspension of Efavirenz for the treatment of neuro-AIDS.
Smita Kakad, Sanjay Kshirsagar
doaj +1 more source
HIV preferentially infects microglia, activating IL‐17A‐driven IFN‐γ/STAT1, CEBPB, and NF‐κB signaling that converges with cGAS‐STING and Notch–NEURL1 pathways, promoting neuroinflammation, mitochondrial dysfunction, and synaptic impairment. cART suppresses viral replication, attenuates inflammatory signaling, and at least partially restores ...
Karthick Chennakesavan +7 more
wiley +1 more source
Objective: To investigate the influence of ABCB1 polymorphisms on the plasma level of efavirenz in Thai adult cases infected with HIV-1. Methods: A single nucleotide polymorphism of ABCB1 3435C>T (rs1045642) in the gene encoding ABCB1 was genotyped using
Sahapat Barusrux +8 more
doaj +1 more source
CYP3A5 genetic variability influences sildenafil and metabolite in pulmonary hypertension
Aim Interindividual variability in sildenafil response among pulmonary hypertension patients (PH) may be influenced by CYP3A5 polymorphisms. CYP3A5*3 allele reduces CYP3A5 activity and affects sildenafil metabolism. This study investigated the associations between CYP3A5 genotype and plasma concentrations of sildenafil and N‐desmethyl sildenafil, as ...
Pranisa Wongwien +7 more
wiley +1 more source
Aims Careful consideration of drug–drug interactions (DDIs) is critical as people with HIV age. We analysed queries submitted to the University of Liverpool HIV Drug Interactions Database to assess changes in prescribing patterns over 5 years. Methods Queries submitted between January 2020 and December 2024 were extracted and categorized by year ...
Cecile Gras +6 more
wiley +1 more source
Pharmacokinetic interactions between rifampicin and efavirenz in HIV-TB coinfections
The increased percentage of patients with HIV-TB coinfection leads to inevitable interactions between rifampicin and efavirenz. Efavirenz is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV infection.
Yenny Yenny
doaj +1 more source
Background Efavirenz is an anti-HIV drug, and cytochrome P450 46A1 (CYP46A1) is a CNS-specific enzyme that metabolizes cholesterol to 24-hydroxycholesterol (24HC).
Alan J. Lerner +12 more
doaj +1 more source
ABSTRACT Hepatocytes perform essential physiological functions in the human body. Gaining more profound insight into the liver structure, diseases, and physiology by using in vitro models can help to propose more relevant clinical applications. Conventional in vitro liver models, such as two‐dimensional (2D) cell cultures, fail to adequately replicate ...
Seyedeh Kiana Teymorian +3 more
wiley +1 more source
Background: Efavirenz is associated with neuropsychiatric side effects. The consequences of using efavirenz in human immunodeficiency virus (HIV)-positive patients with mental illness has not been conclusively established, the concern being that ...
Razia Gaida +2 more
doaj +1 more source
Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim +9 more
wiley +1 more source

